506 related articles for article (PubMed ID: 31641522)
1. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands.
Hunt B; Malkin SJP; Moes RGJ; Huisman EL; Vandebrouck T; Wolffenbuttel BHR
BMJ Open Diabetes Res Care; 2019; 7(1):e000705. PubMed ID: 31641522
[TBL] [Abstract][Full Text] [Related]
2. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
Malkin SJP; Russel-Szymczyk M; Psota M; Hlavinkova L; Hunt B
Adv Ther; 2019 Aug; 36(8):2034-2051. PubMed ID: 31168765
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting.
Martín V; Vidal J; Malkin SJP; Hallén N; Hunt B
Adv Ther; 2020 Oct; 37(10):4427-4445. PubMed ID: 32862365
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan.
Ishii H; Madin-Warburton M; Strizek A; Thornton-Jones L; Suzuki S
J Med Econ; 2018 May; 21(5):488-496. PubMed ID: 29357718
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK.
Viljoen A; Hoxer CS; Johansen P; Malkin S; Hunt B; Bain SC
Diabetes Obes Metab; 2019 Mar; 21(3):611-621. PubMed ID: 30362224
[TBL] [Abstract][Full Text] [Related]
6. A cost-utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada.
Pollock RF; Norrbacka K; Cameron C; Mancillas-Adame L; Jeddi M
J Comp Eff Res; 2019 Mar; 8(4):229-240. PubMed ID: 30644328
[TBL] [Abstract][Full Text] [Related]
7. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
Gorgojo-Martínez JJ; Malkin SJP; Martín V; Hallén N; Hunt B
J Med Econ; 2020 Feb; 23(2):193-203. PubMed ID: 31613199
[No Abstract] [Full Text] [Related]
8. Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden.
Ericsson Å; Fridhammar A
J Med Econ; 2019 Oct; 22(10):997-1005. PubMed ID: 31044636
[No Abstract] [Full Text] [Related]
9. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M
Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244
[TBL] [Abstract][Full Text] [Related]
10. The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials.
Malkin SJP; Hunt B; Huisman EL; Grand TS; Chubb B
Diabetes Res Clin Pract; 2021 May; 175():108759. PubMed ID: 33744377
[TBL] [Abstract][Full Text] [Related]
11. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
Johansen P; Sandberg A; Capehorn M
Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
[TBL] [Abstract][Full Text] [Related]
12. Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16).
Pollock RF; Valentine WJ; Marso SP; Andersen A; Gundgaard J; Hallén N; Tutkunkardas D; Magnuson EA; Buse JB;
Appl Health Econ Health Policy; 2019 Oct; 17(5):615-627. PubMed ID: 31264138
[TBL] [Abstract][Full Text] [Related]
13. Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US.
Dempsey M; Mocarski M; Langer J; Hunt B
J Med Econ; 2018 Nov; 21(11):1110-1118. PubMed ID: 30114954
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria.
Russel-Szymczyk M; Valov V; Savova A; Manova M
BMC Endocr Disord; 2019 Dec; 19(1):132. PubMed ID: 31796048
[TBL] [Abstract][Full Text] [Related]
15. Ideglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared with Insulin Glargine U100 Plus Insulin Aspart in the U.S.
Dempsey M; Mocarski M; Langer J; Hunt B
Endocr Pract; 2018 Sep; 24(9):796-804. PubMed ID: 30308134
[TBL] [Abstract][Full Text] [Related]
16. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
[No Abstract] [Full Text] [Related]
17. Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia.
Malkin SJP; Russel-Szymczyk M; Liidemann G; Volke V; Hunt B
Diabetes Ther; 2019 Feb; 10(1):159-176. PubMed ID: 30535837
[TBL] [Abstract][Full Text] [Related]
18. The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal.
Malkin SJP; Carvalho D; Costa C; Conde V; Hunt B
Diabetol Metab Syndr; 2022 Feb; 14(1):32. PubMed ID: 35164855
[TBL] [Abstract][Full Text] [Related]
19. Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.
Gæde P; Johansen P; Tikkanen CK; Pollock RF; Hunt B; Malkin SJP
Diabetes Ther; 2019 Aug; 10(4):1297-1317. PubMed ID: 31098942
[TBL] [Abstract][Full Text] [Related]
20. The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.
Franch-Nadal J; Malkin SJP; Hunt B; Martín V; Gallego Estébanez M; Vidal J
Adv Ther; 2022 Jul; 39(7):3180-3198. PubMed ID: 35553372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
